Why Chinese Buyers Would Want to Acquire GNC

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why Chinese Buyers Would Want to Acquire GNC

© Thinkstock

GNC Holdings Inc. (NYSE: GNC) could be up for grabs, according to a recent Wall Street Journal report. The important question in this discussion is not necessarily how much the nutritional supplement provider will go for, but who is buying it and why.

It’s worth noting that GNC put itself out there aboutfive months ago, and since it has been weighing options from multiple suitors.

Wall Street Journal reported on Wednesday morning that GNC officials have met with Chinese buyers over the past few weeks. All of this has been in an effort to gauge interest in the deal. Speculatively, the transaction is expected to be valued up to about $4 billion, the current market cap is about $1.4 billion.

But why is China so interested in GNC?

[nativounit]

It is well known that Chinese nationals have been reported as wanting to only buy U.S. vitamins and minerals as the result of so much fraud within the industry in China. Not to mention outright poor quality issues have been rampant.

So effectively China is looking to make a market for U.S. branded vitamins, minerals and supplements.

On the other hand, there could be fallout from U.S. consumers. With fraud and quality controls plaguing this particular industry in China, it could be argued that these Chinese buyers might treat GNC the same way they have treated companies within their own country. In a sense only buying GNC for the brand name.

What is for sure is that nothing has been set in stone yet, and investors seem very happy with the gains that they are seeing for now.

Excluding Wednesday’s move, GNC has underperformed the broad markets, with the stock down about 36% year to date. Over the past 52 weeks, the stock is down about 51%.

Shares of GNC were trading up almost 12% at $21.69 on Wednesday, with a consensus analyst price target of $24.88 and a 52-week trading range of $18.92 to $40.84.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618